Previous studies provided evidence for the direct involvement of IGFBP-3 in metabolic disorders, as increased IGFBP-3 fragments in circulation have been observed in catabolic states such as diabetes and obesity, leading to a decrease in total IGFBP-3 concentration [10, 46]. This evidence concerns the gene IGFBP3 and Other metabolic disease.